Latest & greatest articles for aspirin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aspirin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aspirin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Aspirin

Acetylsalicylic acid (ASA) more commonly known as aspirin is a painkiller that has a wide range of uses. It is frequently used to treat fever, mild pain, tooth aches, headaches and muscle aches. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) and can be used in the management of conditions such as heart attack, arthritis, blood clots and stroke. Aspirin, has been used for thousands of years, initially extracted from the leaves of willow trees.

Aspirin works in much the same way as other NSAIDs but has additional properties, such as antiplatelet activity which can make it additionally useful. More recently aspirin has been linked with cancer prevention. But the potential benefits of aspirin need to be weighed against the potential side effects, which includes gastrointestinal bleeding and Reye’s syndrome. It should be noted that aspirin should not be used in people who are allergic to drugs such as ibuprofen or a more generalized intolerance to NSAIDs. It should also be used cautiously in asthmatics and/or those with bronchospasm associated with NSAID use.

Research evidence, clinical trials and guidelines on Aspirin

The Trip Database has an extensive collection of articles on aspirin ranging from clinical trials, systematic reviews, clinical guidelines and case reports. These can be found via searching the site.

Top results for aspirin

421. Gastric lavage in aspirin and non-steroidal anti-inflammatory drug overdose

Gastric lavage in aspirin and non-steroidal anti-inflammatory drug overdose BestBets: Gastric lavage in aspirin and non-steroidal anti-inflammatory drug overdose Gastric lavage in aspirin and non-steroidal anti-inflammatory drug overdose Report By: Stewart Teece - Clinical Research Fellow Search checked by Ian Crawford - Clinical Research Fellow Institution: Manchester Royal Infirmary Current web editor: Simon Carley - Consultant in Emergency Medicine Date Submitted: 1st March 2000 Date (...) Completed: 2nd September 2004 Last Modified: 5th October 2004 Status: Green (complete) Three Part Question [In overdose with aspirin or other non steroidals] is [gastric lavage better than charcoal or nothing] at [reducing toxicity]? Clinical Scenario A 53 year old widow attends the emergency department having taken 20 aspirin and 20 ibuprofen one and a half hours previously. You remember that non-steroidals slow gastric emptying and wonder whether gastric lavage would be of use in toxicity reduction

2004 BestBETS

422. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. (PubMed)

Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Clopidogrel was superior to aspirin in patients with previous manifestations of atherothrombotic disease in the CAPRIE study and its benefit was amplified in some high-risk subgroups of patients. We aimed to assess whether addition of aspirin to clopidogrel could have a greater benefit than (...) clopidogrel alone in prevention of vascular events with potentially higher bleeding risk.We did a randomised, double-blind, placebo-controlled trial to compare aspirin (75 mg/day) with placebo in 7599 high-risk patients with recent ischaemic stroke or transient ischaemic attack and at least one additional vascular risk factor who were already receiving clopidogrel 75 mg/day. Duration of treatment and follow-up was 18 months. The primary endpoint was a composite of ischaemic stroke, myocardial infarction

2004 Lancet Controlled trial quality: predicted high

423. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. (PubMed)

Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. Use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) has been associated with a decrease in the risk of several cancers, including breast cancer. NSAIDs inhibit cyclooxygenase activity and thereby reduce prostaglandin synthesis; prostaglandins stimulate aromatase gene expression and thereby stimulate estrogen biosynthesis. Given the importance of estrogen (...) in the pathogenesis of breast cancer, the ability of aspirin and other NSAIDs to protect against breast cancer could vary according to hormone receptor status.To determine the association between the frequency and duration of use of aspirin and other NSAIDs and breast cancer risk and to investigate whether any observed association is more pronounced for women with hormone receptor-positive breast cancers.Population-based case-control study of women with breast cancer, including in-person interviews conducted

Full Text available with Trip Pro

2004 JAMA

424. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. (PubMed)

Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. To reassess the prevalence of aspirin induced asthma and other issues related to the syndrome.Biosis, SciSearch (1990 to March 2002), Embase (1974 to March 2002), Medline (1966 to March 2002), Toxline, Derwent Drug File (1964 to March 2002), Conference Papers Index and Inside Conferences, Int'l Pharmaceutical Abstracts, Pharma-Online (1978 to March 2002).Study type, patient population (...) , and outcome measures. Review was restricted to respiratory responses to analgesics available without prescription.The prevalence of aspirin induced asthma was highest when determined by oral provocation testing (adults 21%, 95% confidence interval 14% to 29%; children 5%, 0% to 14%) than by verbal history (adults 3%, 2% to 4%; children 2%, 1% to 3%). Cross sensitivity to doses of over the counter non-steroidal anti-inflammatory drugs was present in most patients with aspirin induced asthma: ibuprofen, 98

Full Text available with Trip Pro

2004 BMJ

425. A prospective study of aspirin use and the risk for colorectal adenoma. (PubMed)

A prospective study of aspirin use and the risk for colorectal adenoma. Randomized, double-blind, placebo-controlled trials have established that regular aspirin use reduces the risk for recurrent colorectal adenoma. However, the effect of dose and duration of use, particularly in an average-risk population, is not well understood.To examine the influence of dose and duration of aspirin use in the primary prevention of colorectal adenoma.Prospective cohort study.Nurses' Health Study.27 077 (...) women, 34 to 77 years of age, without a history of adenoma, cancer, inflammatory bowel disease, or familial polyposis, who underwent lower endoscopy between 1980 and 1998.1368 cases of confirmed distal colorectal adenoma were diagnosed between 1980 and 1998. Self-reported data on aspirin use were collected from biennial questionnaires.After other risk factors for adenoma were adjusted, women who regularly used aspirin (> or =2 standard aspirin tablets/wk) had a multivariate relative risk for adenoma

2004 Annals of Internal Medicine

426. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation

Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute (...) coronary syndromes: a systematic review and economic evaluation Main C, Palmer S, Griffin S, Jones L, Orton V, Sculpher M, et al Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Main C, Palmer S, Griffin S, Jones L, Orton V, Sculpher M, et al. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST

2004 Health Technology Assessment (HTA) Database.

427. Economic assessment of the secondary prevention of ischaemic stroke with dipyridamole plus aspirin (Aggrenox/Asasantin) in France

Economic assessment of the secondary prevention of ischaemic stroke with dipyridamole plus aspirin (Aggrenox/Asasantin) in France Economic assessment of the secondary prevention of ischaemic stroke with dipyridamole plus aspirin (Aggrenox/Asasantin) in France Economic assessment of the secondary prevention of ischaemic stroke with dipyridamole plus aspirin (Aggrenox/Asasantin) in France Marissal J P, Selke B, Amarenco P Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of aspirin 25 mg plus dipyridamole 200 mg, twice daily, for the secondary prevention of ischaemic stroke. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised

2004 NHS Economic Evaluation Database.

428. Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus

Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus Hur C, Nishioka N S, Gazelle G S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology Four strategies for the management of Barrett's oesophagus (BE) to prevent oesophageal adenocarcinoma were studied. The strategies were aspirin therapy, endoscopic surveillance with biopsies, both, or neither. Type of intervention Secondary prevention. Economic study type Cost-utility analysis. Study population The hypothetical population was a cohort of 50,000 55-year-old men who had BE proven by endoscopic biopsy. The reason

2004 NHS Economic Evaluation Database.

429. The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individuals

The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individuals The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individuals The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individuals Hur C, Simon L S, Gazelle G S Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of aspirin versus cyclooxygenase-2-selective inhibitors (coxibs) as primary chemoprevention for colorectal carcinoma (CRC). Type of intervention Primary prevention. Economic study type Cost-utility analysis

Full Text available with Trip Pro

2004 NHS Economic Evaluation Database.

430. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation

Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute (...) the use of 12-month clopidogrel in combination with aspirin for the prevention of morbidity and mortality associated with non-ST-segment elevation acute coronary syndrome (ACS). The combined therapy was compared with standard therapy including aspirin. Three alternative strategies (representing treatment with clopidogrel over a 1-, 3- or 6-month duration) were also considered. Type of intervention Secondary prevention. Economic study type Cost-utility analysis Study population The study population

2004 NHS Economic Evaluation Database.

431. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis

Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis Schleinitz M D, Weiss J P, Owens D K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two alternative antiplatelet therapies, aspirin (325 mg orally per day) and clopidogrel (75 mg orally per day), were examined. Type of intervention Secondary prevention. Economic study type Cost-utility analysis. Study population The study population comprised a hypothetical cohort of patients with peripheral arterial disease, a non

2004 NHS Economic Evaluation Database.

432. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation

Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute (...) coronary syndromes: a systematic review and economic evaluation Main C, Palmer S, Griffin S, Jones L, Orton V, Sculpher M, Henderson R, Sudlow C, Hawkins N, Riemsma R CRD summary This review found that clopidogrel in combination with standard therapy was significantly more effective than aspirin alone for the treatment of acute coronary syndromes. Overall, this was a well-conducted review and the authors' conclusions are supported by the evidence presented. Authors' objectives To review the clinical

2004 DARE.

433. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice

Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 DARE.

434. Efficacy and safety of low-dose aspirin in polycythemia vera. (PubMed)

Efficacy and safety of low-dose aspirin in polycythemia vera. The use of aspirin for the prevention of thrombotic complications in polycythemia vera is controversial.We enrolled 518 patients with polycythemia vera, no clear indication for aspirin treatment, and no contraindication to such treatment in a double-blind, placebo-controlled, randomized trial to assess the safety and efficacy of prophylaxis with low-dose aspirin (100 mg daily). The two primary end points were the cumulative rate (...) of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes and the cumulative rate of nonfatal myocardial infarction, nonfatal stroke, pulmonary embolism, major venous thrombosis, or death from cardiovascular causes. The mean duration of follow-up was about three years.Treatment with aspirin, as compared with placebo, reduced the risk of the combined end point of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes (relative risk, 0.41; 95

Full Text available with Trip Pro

2004 NEJM Controlled trial quality: predicted high

435. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. (PubMed)

Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. Enoxaparin or the combination of glycoprotein IIb/IIIa inhibitor tirofiban with unfractionated heparin independently have shown superior efficacy over unfractionated heparin alone in patients with non-ST-elevation acute coronary syndromes (ACS). It is not clear if combining enoxaparin with glycoprotein (...) heparin (n = 1961) in patients with non-ST-elevation ACS receiving tirofiban and aspirin. Phase A of the A to Z trial was conducted between December 1999 and May 2002.Death, recurrent myocardial infarction, or refractory ischemia at 7 days in the intent-to-treat population with boundaries set for superiority and noninferiority. Safety based on measures of bleeding using the Thrombolysis in Myocardial Infarction (TIMI) classification system.A total of 169 (8.4%) of 2018 patients randomized

Full Text available with Trip Pro

2004 JAMA Controlled trial quality: predicted high

436. Effect of ibuprofen on cardioprotective effect of aspirin. (PubMed)

Effect of ibuprofen on cardioprotective effect of aspirin. Treatment with ibuprofen might limit the cardioprotective effects of aspirin. We aimed to assess whether patients with known cardiovascular disease who take low-dose aspirin and ibuprofen have increased risk of cardiovascular mortality. We studied 7107 patients who were discharged after first admission for cardiovascular disease between April, 1989, and April, 1997, and who were prescribed low-dose aspirin (<325 mg/day) and survived (...) for at least 1 month. Compared with those who used aspirin alone, patients taking aspirin plus ibuprofen had an increased risk of all-cause mortality (adjusted hazard ratio 1.93, 95% CI 1.30-2.87, p=0.0011) and cardiovascular mortality (1.73, 1.05-2.84, p=0.0305). Our finding lends support to the hypothesis that ibuprofen may interact with the cardioprotective effects of aspirin, at least in patients with established cardiovascular disease.

2003 Lancet

437. Indirect comparison meta-analysis of aspirin therapy after coronary surgery. (PubMed)

Indirect comparison meta-analysis of aspirin therapy after coronary surgery. To evaluate the efficacy of low and medium dose aspirin therapy after coronary surgery by using an indirect comparison meta-analysis.Systematic literature search of Medline, Embase, Cochrane controlled trials register, and trial register sites on the internet.Outcome was evaluated by angiography and reported as graft occlusion and rate of events in patients. Trials that did not include aspirin as the sole therapy (...) or did not have a placebo control arm were excluded. Articles were assessed for eligibility and quality and grouped according to dosage. The estimated difference in effect of low and medium dose aspirin on graft occlusion was obtained by combining the estimated log relative risks of low dose with placebo and medium dose with placebo.For graft occlusion, the medium dose trials yielded a relative risk reduction of 45% compared with 26% for the low dose trials. The greater effect in the medium dose

Full Text available with Trip Pro

2003 BMJ

438. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review

Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review Coomarasamy A, Honest H, Papaioannou S, Gee H, Khan K S CRD summary This review examined the effectiveness of aspirin in preventing perinatal death and pre-eclampsia in women with predisposing factors (...) . The authors concluded that aspirin can reduce the risk of pre-eclampsia and perinatal death in women who have known historical risk factors. Statements on the safety of aspirin were derived largely from observational studies, which were not part of the current systematic review. Authors' objectives To examine the effectiveness of aspirin in preventing perinatal death and pre-eclampsia in women with predisposing factors. Searching MEDLINE (from 1966 to 2001), EMBASE (from 1980 to 2001), the Cochrane

2003 DARE.

439. Cost-effectiveness analysis of clopidogrel versus aspirin in patients with atherothrombosis based on the CAPRIE trial

Cost-effectiveness analysis of clopidogrel versus aspirin in patients with atherothrombosis based on the CAPRIE trial Cost-effectiveness analysis of clopidogrel versus aspirin in patients with atherothrombosis based on the CAPRIE trial Cost-effectiveness analysis of clopidogrel versus aspirin in patients with atherothrombosis based on the CAPRIE trial Annemans L, Lamotte M, Levy E, Lenne X Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) , or symptomatic PAD. The mean age was 62.5 years. There were 9,553 patients in the clopidogrel group and 9,546 in the aspirin group. Additional information was taken from the CAPRIE study. Study design The study was an international, multi-centre, randomised controlled trial, with an average follow-up of 1.91 years. A total of 384 clinical centres from 16 countries participated. The patients were randomised to either 75-mg tablets of clopidogrel plus aspirin placebo or 325-mg tablets of aspirin plus

2003 NHS Economic Evaluation Database.

440. Indirect comparison meta-analysis of aspirin therapy after coronary surgery

Indirect comparison meta-analysis of aspirin therapy after coronary surgery Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 DARE.